Quantitative Drug Benefit-Risk Assessment: Utility of Modeling and Simulation to Optimize Drug Safety in Older Adults

Victor Crentsil, Jung Lee, Andre Jackson

Research output: Contribution to journalArticle

Abstract

Background: More than 50 % of individuals affected by adverse drug events (ADEs) are older adults. Establishing a drug dosing regimen that balances benefit and risk, and minimizes ADEs in older populations can be challenging. Objective: The aim of this study is to evaluate the use of modeling, simulation, and risk-benefit acceptability methods to establish a drug dosing regimen that balances benefit and risk. Methods: The study population comprised nondiabetic patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) ≥50 years old, who had been on oral olanzapine for ≥2 weeks. We used mixed-effects modeling based on a preexisting pharmacokinetic model to derive clearance estimates, which were then used to determine the olanzapine area under the concentration-time curve (AUC). Subsequently, with multivariate regression and Monte Carlo simulation, we estimated the olanzapine dose corresponding to the benefit-risk AUC breakpoint. Results: The study population (n = 34) was predominantly male (82.3%) and white (67.6%), with a mean age of 54.4 years and treatment duration of 361.8 days. The mean AUC was 747.6 ng h/mL (95% CI = 524.5, 970.7) for the benefit group (n = 16) and 754.1 (95% CI = 505.9, 1002.4) for the risk group (n = 15). The benefit-risk AUC breakpoint was 524.5 ng h/mL and the corresponding oral olanzapine dose that optimizes benefit-risk balance was 17.8 mg/d. Conclusions: Our study introduces a real-world approach for finding the safe drug dosing regimen without extensive exposure of a vulnerable and older population to drugs. Further studies into the use of modeling, simulation, and risk-benefit acceptability methods to enhance geriatric drug safety are needed.

Original languageEnglish (US)
Pages (from-to)306-313
Number of pages8
JournalAnnals of Pharmacotherapy
Volume48
Issue number3
DOIs
StatePublished - Mar 2014
Externally publishedYes

Fingerprint

olanzapine
Safety
Pharmaceutical Preparations
Drug-Related Side Effects and Adverse Reactions
Population
Vulnerable Populations
Geriatrics
Antipsychotic Agents
Schizophrenia
Pharmacokinetics
Clinical Trials

Keywords

  • drug dosing
  • geriatric
  • modeling
  • risk-benefit acceptability threshold
  • simulation

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Quantitative Drug Benefit-Risk Assessment : Utility of Modeling and Simulation to Optimize Drug Safety in Older Adults. / Crentsil, Victor; Lee, Jung; Jackson, Andre.

In: Annals of Pharmacotherapy, Vol. 48, No. 3, 03.2014, p. 306-313.

Research output: Contribution to journalArticle

@article{7dacd8d6d07946e7866cdefd0dfe8e64,
title = "Quantitative Drug Benefit-Risk Assessment: Utility of Modeling and Simulation to Optimize Drug Safety in Older Adults",
abstract = "Background: More than 50 {\%} of individuals affected by adverse drug events (ADEs) are older adults. Establishing a drug dosing regimen that balances benefit and risk, and minimizes ADEs in older populations can be challenging. Objective: The aim of this study is to evaluate the use of modeling, simulation, and risk-benefit acceptability methods to establish a drug dosing regimen that balances benefit and risk. Methods: The study population comprised nondiabetic patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) ≥50 years old, who had been on oral olanzapine for ≥2 weeks. We used mixed-effects modeling based on a preexisting pharmacokinetic model to derive clearance estimates, which were then used to determine the olanzapine area under the concentration-time curve (AUC). Subsequently, with multivariate regression and Monte Carlo simulation, we estimated the olanzapine dose corresponding to the benefit-risk AUC breakpoint. Results: The study population (n = 34) was predominantly male (82.3{\%}) and white (67.6{\%}), with a mean age of 54.4 years and treatment duration of 361.8 days. The mean AUC was 747.6 ng h/mL (95{\%} CI = 524.5, 970.7) for the benefit group (n = 16) and 754.1 (95{\%} CI = 505.9, 1002.4) for the risk group (n = 15). The benefit-risk AUC breakpoint was 524.5 ng h/mL and the corresponding oral olanzapine dose that optimizes benefit-risk balance was 17.8 mg/d. Conclusions: Our study introduces a real-world approach for finding the safe drug dosing regimen without extensive exposure of a vulnerable and older population to drugs. Further studies into the use of modeling, simulation, and risk-benefit acceptability methods to enhance geriatric drug safety are needed.",
keywords = "drug dosing, geriatric, modeling, risk-benefit acceptability threshold, simulation",
author = "Victor Crentsil and Jung Lee and Andre Jackson",
year = "2014",
month = "3",
doi = "10.1177/1060028013514376",
language = "English (US)",
volume = "48",
pages = "306--313",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "3",

}

TY - JOUR

T1 - Quantitative Drug Benefit-Risk Assessment

T2 - Utility of Modeling and Simulation to Optimize Drug Safety in Older Adults

AU - Crentsil, Victor

AU - Lee, Jung

AU - Jackson, Andre

PY - 2014/3

Y1 - 2014/3

N2 - Background: More than 50 % of individuals affected by adverse drug events (ADEs) are older adults. Establishing a drug dosing regimen that balances benefit and risk, and minimizes ADEs in older populations can be challenging. Objective: The aim of this study is to evaluate the use of modeling, simulation, and risk-benefit acceptability methods to establish a drug dosing regimen that balances benefit and risk. Methods: The study population comprised nondiabetic patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) ≥50 years old, who had been on oral olanzapine for ≥2 weeks. We used mixed-effects modeling based on a preexisting pharmacokinetic model to derive clearance estimates, which were then used to determine the olanzapine area under the concentration-time curve (AUC). Subsequently, with multivariate regression and Monte Carlo simulation, we estimated the olanzapine dose corresponding to the benefit-risk AUC breakpoint. Results: The study population (n = 34) was predominantly male (82.3%) and white (67.6%), with a mean age of 54.4 years and treatment duration of 361.8 days. The mean AUC was 747.6 ng h/mL (95% CI = 524.5, 970.7) for the benefit group (n = 16) and 754.1 (95% CI = 505.9, 1002.4) for the risk group (n = 15). The benefit-risk AUC breakpoint was 524.5 ng h/mL and the corresponding oral olanzapine dose that optimizes benefit-risk balance was 17.8 mg/d. Conclusions: Our study introduces a real-world approach for finding the safe drug dosing regimen without extensive exposure of a vulnerable and older population to drugs. Further studies into the use of modeling, simulation, and risk-benefit acceptability methods to enhance geriatric drug safety are needed.

AB - Background: More than 50 % of individuals affected by adverse drug events (ADEs) are older adults. Establishing a drug dosing regimen that balances benefit and risk, and minimizes ADEs in older populations can be challenging. Objective: The aim of this study is to evaluate the use of modeling, simulation, and risk-benefit acceptability methods to establish a drug dosing regimen that balances benefit and risk. Methods: The study population comprised nondiabetic patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) ≥50 years old, who had been on oral olanzapine for ≥2 weeks. We used mixed-effects modeling based on a preexisting pharmacokinetic model to derive clearance estimates, which were then used to determine the olanzapine area under the concentration-time curve (AUC). Subsequently, with multivariate regression and Monte Carlo simulation, we estimated the olanzapine dose corresponding to the benefit-risk AUC breakpoint. Results: The study population (n = 34) was predominantly male (82.3%) and white (67.6%), with a mean age of 54.4 years and treatment duration of 361.8 days. The mean AUC was 747.6 ng h/mL (95% CI = 524.5, 970.7) for the benefit group (n = 16) and 754.1 (95% CI = 505.9, 1002.4) for the risk group (n = 15). The benefit-risk AUC breakpoint was 524.5 ng h/mL and the corresponding oral olanzapine dose that optimizes benefit-risk balance was 17.8 mg/d. Conclusions: Our study introduces a real-world approach for finding the safe drug dosing regimen without extensive exposure of a vulnerable and older population to drugs. Further studies into the use of modeling, simulation, and risk-benefit acceptability methods to enhance geriatric drug safety are needed.

KW - drug dosing

KW - geriatric

KW - modeling

KW - risk-benefit acceptability threshold

KW - simulation

UR - http://www.scopus.com/inward/record.url?scp=84896855019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896855019&partnerID=8YFLogxK

U2 - 10.1177/1060028013514376

DO - 10.1177/1060028013514376

M3 - Article

C2 - 24473487

AN - SCOPUS:84896855019

VL - 48

SP - 306

EP - 313

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 3

ER -